Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adultsGORSE, Geoffrey J; BADEN, Lindsey R; RUSSELL, Nina D et al.Vaccine. 2008, Vol 26, Num 2, pp 215-223, issn 0264-410X, 9 p.Article

Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progressionDEMAREST, James F; JACK, Noreen; MAHABIR, Bisram et al.AIDS research and human retroviruses. 2001, Vol 17, Num 14, pp 1333-1344, issn 0889-2229Article

Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial ViremiaTOMARAS, Georgia D; YATES, Nicole L; COHEN, Myron et al.Journal of virology. 2008, Vol 82, Num 24, pp 12449-12463, issn 0022-538X, 15 p.Article

Prolonged CD4⁺ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: Immune response and oral controlSUFKA, Susan A; FERRARI, Guido; WEINHOLD, Kent J et al.The Journal of infectious diseases. 2003, Vol 187, Num 7, pp 1027-1037, issn 0022-1899, 11 p.Article

In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization BreadthXIAOYING SHEN; PARKS, Robert J; GREENBERG, Michael L et al.Journal of virology. 2009, Vol 83, Num 8, pp 3617-3625, issn 0022-538X, 9 p.Article

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G proteinWRIGHT, Peter F; MESTECKY, Jiri; SPRING, Michele D et al.The Journal of infectious diseases. 2004, Vol 189, Num 7, pp 1221-1231, issn 0022-1899, 11 p.Article

Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccinesFERRARI, Guido; KOSTYU, Donna D; COX, Josephine et al.AIDS research and human retroviruses. 2000, Vol 16, Num 14, pp 1433-1443, issn 0889-2229Article

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. CommentaryROHINSON, Harriet L; WEINHOLD, Kent J; NOVIK, Laura et al.The Journal of infectious diseases. 2006, Vol 194, Num 12, issn 0022-1899, 1625-1627,1638-1649 [15 p.]Article

Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapyWELLONS, Melissa F; OTTINGER, Janet S; WEINHOLD, Kent J et al.The Journal of infectious diseases. 2001, Vol 183, Num 10, pp 1522-1525, issn 0022-1899Article

Thymopoiesis in HIV-infected adults after highly active antiretroviral therapyMARKERT, M. Louise; ALVAREZ-MCLEOD, Africa P; SEMPOWSKI, Gregory D et al.AIDS research and human retroviruses. 2001, Vol 17, Num 17, pp 1635-1643, issn 0889-2229Article

Initial HIV-1 Antigen-Specific CD8⁺ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus ReplicationFREEL, Stephanie A; PICKING, Ralph A; DENNY, Thomas N et al.Journal of virology. 2012, Vol 86, Num 12, pp 6835-6846, issn 0022-538X, 12 p.Article

Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission : Implications for HIV-1 Vaccine DesignGASPER-SMITH, Nancy; CROSSMAN, Deanna M; REICH, Charles F et al.Journal of virology. 2008, Vol 82, Num 15, pp 7700-7710, issn 0022-538X, 11 p.Article

Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4⁺/viral load discordanceKAPLAN, Susan S; FERRARI, Guido; WRIN, Terri et al.AIDS research and human retroviruses. 2005, Vol 21, Num 1, pp 13-16, issn 0889-2229, 4 p.Article

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccinesMONTEFIORI, David C; METCH, Barbara; MCELRATH, M. Juliana et al.The Journal of infectious diseases. 2004, Vol 190, Num 11, pp 1962-1969, issn 0022-1899, 8 p.Article

Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost VaccinationFREEL, Stephanie A; LAMOREAUX, Laurie; DENNY, Thomas N et al.Journal of virology. 2010, Vol 84, Num 10, pp 4998-5006, issn 0022-538X, 9 p.Article

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trialSPEARMAN, Paul; KALAMS, Spyros; FREY, Sharon E et al.Vaccine. 2009, Vol 27, Num 2, pp 243-249, issn 0264-410X, 7 p.Article

Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes : Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute InfectionALAM, S. Munir; SCEARCE, Richard M; XIA, Shi-Mao et al.Journal of virology. 2008, Vol 82, Num 1, pp 115-125, issn 0022-538X, 11 p.Article

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120 : Negative results fail to trigger a phase 3 correlates trialRUSSELL, Nina D; GRAHAM, Barney S; GURUNATHAN, Sanjay et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 44, Num 2, pp 203-212, issn 1525-4135, 10 p.Article